Anyone with lungs can get lung cancer. But not everyone has access to the insights that can change its course.

Every lung tumor carries a unique molecular signature that determines how it evolves and how it can be treated. Yet too many patients receive care without this knowledge guiding the way.

Cancers with RAS mutations (KRAS, NRAS, HRAS) continue to show us that targeting a single mutation isn’t always enough: when you block one RAS-driven pathway, the tumor may simply switch to another. At Genomate Health, this is exactly the kind of complexity we help clinicians navigate.

#ESMO2025 made one thing clear: oncology is shifting from empirical decision-making to a molecularly defined, data-driven discipline.

#ComputationalReasoning #ClinicalValidation #GenomateHealth

Our results provide strong evidence that knowledge-graph-based computational reasoning enables consistent and reproducible MTA assignments, with the potential to identify patients who are most likely to benefit from precision oncology compared to standard chemotherapy.

Thrilled to be presenting our latest work at the AACR-KCA Conference on Precision Medicine in Cancer!

Our study evaluates the Digital Drug Assignment system (Genomate), a knowledge-graph-based computational reasoning tool designed to support treatment decision-making in precision oncology.

In a study published in the WJ of Pediatrics, Genomate was evaluated for its real-world performance in pediatric oncology. It shows that Genomate can identify clinically relevant targeted therapy options, providing clarity and more choices, even in complex cases: link.springer.com/article/10.1...

In our latest feature for West Midlands Life Sciences Week, we explore the growing gap between innovation and impact in cancer care, and why more data alone isn’t the answer: wmlifesciencesweek.co.uk/the-case-for...

#PrecisionOncology #ComputationalReasoning #Genomate

In just 10 minutes, he shares:
✅ Why today’s innovations often don’t reach the patients who need them
✅ How computational reasoning can help standardize care across borders
✅ What it takes to make precision oncology truly accessible

Join the event here: www.technologynetworks.com/tn/online-ev...

Next week, Dr. Istvan Petak, founder and CSO of Genomate Health, joins Teach Me in 10 to ask a tough but timely question: 𝐂𝐚𝐧 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐭𝐫𝐮𝐥𝐲 𝐛𝐞 𝐞𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞?

Join him as he shares what’s needed to turn technology into impact, for every patient: www.technologynetworks.com/tn/online-ev...

We’re constantly reminded of the power of friendship: the friends who drive to appointments, who ask the hard questions, who sit in silence when there’s nothing to say.

This #WorldFriendshipDay, we honor them. Because while we focus on precision, they provide something just as important: presence.

Our recent study shows that patients who received treatment recommended by Genomate lived longer, responded better, and had more treatment options based on their molecular profile.

Because lung cancer isn’t one-size-fits-all. And treatments shouldn’t be either: www.genomate.health/publication/...

Here’s what makes Genomate different:
🔍 We alert oncologists to the most important genetic alteration, so they know where to focus first
⚠️ We flag resistance mechanisms, helping avoid therapies likely to fail
🎯 We optimize for maximum clinical benefit, going beyond matching drugs to mutations

How does Genomate® help oncologists make smarter, more confident treatment decisions?

Our latest study, published in @nature.com’s npj Precision Oncology, shows how Genomate doesn’t just analyze molecular data. It translates it into action.

In other words: we bring clarity to complexity.